Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.65 |
| ▸ | NOD1 | Q9Y239 | 9/20 | 0.47 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.40 |
| ▸ | CCKAR | P32238 | 2/20 | 0.39 |
| ▸ | CCKBR | P32239 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16182595 | 1.00 | GLP1R (0.65) | GLP1RNOD1GLO1CCKARCCKBR | |
| SCHEMBL12807352 | 1.00 | GLP1R (0.65) | GLP1RNOD1GLO1CCKARCCKBR | |
| SCHEMBL20665111 | 0.98 | GLP1R (0.64) | GLP1RNOD1GLO1 | |
| SCHEMBL17570497 | 0.94 | GLP1R (0.67) | GLP1RNOD1GLO1CCKARCCKBR | |
| SCHEMBL24198476 | 0.94 | GLP1R (0.67) | GLP1RNOD1GLO1CCKARCCKBR | |
| SCHEMBL20911267 | 0.94 | GLP1R (0.67) | GLP1RNOD1GLO1CCKARCCKBR | |
| SCHEMBL23051891 | 0.94 | GLP1R (0.67) | GLP1RNOD1GLO1CCKARCCKBR | |
| SCHEMBL24284196 | 0.94 | GLP1R (0.67) | GLP1RNOD1GLO1CCKARCCKBR | |
| SCHEMBL24899310 | 0.94 | GLP1R (0.67) | GLP1RNOD1GLO1CCKARCCKBR | |
| SCHEMBL17570507 | 0.94 | GLP1R (0.67) | GLP1RNOD1GLO1CCKARCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241178-A1 | LONG ACTING GLP-1/GIP DUAL AGONISTS | SUN PHARMACEUTICAL IND LTD (IN) | 2023-08-03 | — | — | US | disclosed |
| US-11649269-B2 | Bifunctional compounds comprising insulin peptides and EGF(A) peptides | NOVO NORDISK A/S (DK) | 2023-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241178-A1 | LONG ACTING GLP-1/GIP DUAL AGONISTS | GLP1R, GIPR, GPR119 | GLP1R 1/4885NOD1 1941/4885GLO1 1859/4885 |
| US-11649269-B2 | Bifunctional compounds comprising insulin peptides and EGF(A) peptides | IAPP, IGFBP1, IGFBP2 | GLP1R 16/4885NOD1 2091/4885GLO1 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.